Literature DB >> 35031926

Functions of lncRNA DUXAP8 in non-small cell lung cancer.

Cui Wu1, Wu Song2, Zhongnan Wang3, Bingmei Wang4.   

Abstract

Non-small cell lung cancer (NSCLC) poses a serious threat to public health due to its significant morbidity and mortality rates. The processes of NSCLC formation and development are quite complex and involve numerous regulatory biomolecules. Long non-coding RNAs (lncRNAs) have attracted attention since they have been found to play critical roles in the tumorigenesis of various human malignancies. Recently, double homeobox A pseudogene 8 (DUXAP8) was identified as an oncogenic lncRNA that is overexpressed in different tumor types. In NSCLC, high expression of DUXAP8 is associated with poor prognosis in patients. The regulatory mechanism underlying the oncogenic effects of DUXAP8 can be divided into transcriptional level and post-transcriptional level. DUXAP8 promotes proliferation, epithelial-mesenchymal transition, and aerobic glycolysis in NSCLC cells. Moreover, DUXAP8 shows potential for the diagnosis and treatment of NSCLC. Herein, we review the molecular mechanisms underlying the DUXAP8-mediated phenotypes of NSCLC as well as its potential clinical applications.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  DUXAP8; Long non-coding RNA; Non-small cell lung cancer; Oncogene; Pseudogene

Mesh:

Substances:

Year:  2022        PMID: 35031926     DOI: 10.1007/s11033-021-07066-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  82 in total

1.  Annotation, nomenclature and evolution of four novel homeobox genes expressed in the human germ line.

Authors:  H Anne F Booth; Peter W H Holland
Journal:  Gene       Date:  2006-08-22       Impact factor: 3.688

2.  STAT3-induced upregulation of lncRNA DUXAP8 functions as ceRNA for miR-577 to promote the migration and invasion in colorectal cancer through the regulation of RAB14.

Authors:  C Du; H-X Wang; P Chen; C-H Chen
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-07       Impact factor: 3.507

3.  Erratum to epidemiology, incidence and mortality of lung cancer and their relationship with the development index in the world.

Authors:  Hosein Rafiemanesh; Mojtaba Mehtarpour; Farah Khani; Sayed Mohammadali Hesami; Reza Shamlou; Farhad Towhidi; Hamid Salehiniya; Behnam Reza Makhsosi; Ali Moini
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

Review 4.  Long noncoding RNAs: lincs between human health and disease.

Authors:  Zhi Hao Kwok; Yvonne Tay
Journal:  Biochem Soc Trans       Date:  2017-06-15       Impact factor: 5.407

5.  Multi-subtype classification model for non-small cell lung cancer based on radiomics: SLS model.

Authors:  Jian Liu; Jingjing Cui; Fei Liu; Yixuan Yuan; Feng Guo; Guanglei Zhang
Journal:  Med Phys       Date:  2019-05-11       Impact factor: 4.071

6.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Authors:  Yi-Long Wu; Caicun Zhou; Cheng-Ping Hu; Jifeng Feng; Shun Lu; Yunchao Huang; Wei Li; Mei Hou; Jian Hua Shi; Kye Young Lee; Chong-Rui Xu; Dan Massey; Miyoung Kim; Yang Shi; Sarayut L Geater
Journal:  Lancet Oncol       Date:  2014-01-15       Impact factor: 41.316

7.  Long noncoding RNA DUXAP8 regulates proliferation and apoptosis of ovarian cancer cells via targeting miR-590-5p.

Authors:  Qingyou Meng; Zhongliang Li; Jiaxue Pan; Xiaorong Sun
Journal:  Hum Cell       Date:  2020-08-04       Impact factor: 4.174

8.  The pseudogene derived long noncoding RNA DUXAP8 promotes gastric cancer cell proliferation and migration via epigenetically silencing PLEKHO1 expression.

Authors:  Hong-Wei Ma; Min Xie; Ming Sun; Tian-Yu Chen; Rong-Rong Jin; Tian-Shi Ma; Qin-Nan Chen; Er-Bao Zhang; Xue-Zhi He; Wei De; Zhi-Hong Zhang
Journal:  Oncotarget       Date:  2016-08-05

9.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245

View more
  1 in total

Review 1.  Current treatments for non-small cell lung cancer.

Authors:  Qianqian Guo; Liwei Liu; Zelong Chen; Yannan Fan; Yang Zhou; Ziqiao Yuan; Wenzhou Zhang
Journal:  Front Oncol       Date:  2022-08-11       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.